Document:

CPY Document Title

October 25, 2006
Donald Parman

Vice President and Secretary

SmithKline Beecham Corporation d/b/a GlaxoSmithKline

200 N. 16lh Street Philadelphia, PA 19102 215-751-7633 215-751-5349 (fax)

Genaera Corporation

5110 Campus Drive

Plymouth Meeting, PA 19462

Attn: John L. Armstrong, Jr., President & CEO

Dear Mr. Armstrong:

Reference is hereby made to the Development, Supply and Distribution Agreement between SmithKline Beecham Corporation (d/b/a GlaxoSmithKline) ("GSK") and Genaera Corporation (f/k/a Magainin Pharmaceuticals, Inc.) ("Genaera"), dated February 12, 1997 (the "Agreement"). All capitalized terms used but not defined herein have the meanings ascribed to them in the Agreement.

As you know, the product known in the Agreement as MSI-78, or LOCILEXTM, has been dormant for a number of years, due to the fact that the FDA did not approve LOCILEXTM in 1999 and since then, both GSK and Genaera have refocused development efforts on other programs. In addition, Section 4.1 of the Agreement provided GSK with the exclusive option to obtain the right to exclusively distribute a product of Genaera's other than MSI-78 if MSI-78 failed to obtain regulatory approval in the Territory. GSK acknowledges that it has reviewed Genaera's product portfolio and has opted to not exercise its option and furthermore, that GSK has no further rights under the Agreement to any of Genaera's products. Nothing herein is intended to prevent GSK and Genaera from considering other business transactions in the future, unrelated to the Agreement.

Section 9.4 of the Agreement provides that GSK may terminate the Agreement on a country-by-country basis by giving thirty (30) days written notice to Genaera. The decision to terminate the Agreement is based upon GSK's reasonable determination that, taking into consideration the factors set forth in the preceding paragraph, the medical/scientific, technical, regulatory and/or commercial profile of MSI-78 does not justify continued development thereof. Therefore, this letter serves as notice to Genaera that the Agreement will

terminate in all countries of the Territory, effective thirty (30) days from Genaera's receipt of this notice.
Sincerely,

SMITHKLINE BEECHAM

CORPORATION

(d/b/a GlaxoSmithKline)

By: /s/ Donald F. Parman

Name: Donald F. Parman 

Title: Vice President & SecretaryExhibit 10

Exhibit 10.1

EarthLink, Inc.

Board of Directors Compensation Plan

Effective January 1, 2007

	Retainer

	Each independent director receives a $35,000 annual retainer, paid semi-annually in advance ($17,500 following January Board meeting and $17,500 following July Board meeting).  
	An independent Chairman of the Board receives an additional $20,000 annual retainer, paid semi-annually in advance ($10,000 following the January Board meeting and $10,000 following the July Board meeting).
	The Leadership and Compensation Committee chair, the Corporate Governance and Nominating Committee chair and the Finance Committee chair each receive an additional $10,000 annual retainer, paid semi-annually in advance ($5,000 following January Board meeting and $5,000 following July Board meeting).
	The Audit Committee chair receives an additional $20,000 annual retainer, paid semi-annually in advance ($10,000 following January Board meeting and $10,000 following July Board meeting).
	An independent director designated to serve on the Board of Helio Inc. receives an additional $60,000 annual retainer, paid semi-annually in advance ($30,000 following January Board meeting and $30,000 following July Board meeting).

	Meeting fees

	Each independent director is paid $1,000 for each full Board meeting and Committee meeting he or she attends in person and $500 for each full Board meeting and Committee meeting he or she attends telephonically.
	An independent director designated to serve on the Board of Helio Inc. is paid $1,000 for each full Helio Inc. Board and Committee meeting he or she attends in person and $500 for each full Helio Inc. Board and Committee meeting he or she attends telephonically.

	Stock Options

	Independent directors receive an initial option grant of 15,000 options when they join the Board.  These options vest over four years.
	Additionally, independent directors receive an annual option grant of 10,000 options on the first business day of January of each year.  These also vest over four years.

	Restricted Stock Units

	Each independent director receives a grant of Restricted Stock Units valued at $30,000 annually (on the date of the July Board meeting).  Restricted Stock Units will vest over four years, and upon vesting may be received in shares of stock or may be deferred into a deferred compensation plan.  

	Note:  Each RSU is equal to one share of EarthLink stock.  Upon vesting, the RSUs may be received in shares of stock (in which case the recipient has taxable income equal to the value of the shares received on the date of vesting), or may be deferred into a deferred compensation plan where they continue to be equal to shares of EarthLink stock but where receipt and taxation may be deferred to later dates.

	Stock Appreciation Rights

	An independent director designated to serve on the Board of Helio Inc. receives a Stock Appreciation Right when he or she joins the Helio Inc. Board.  This Stock Appreciation Right provides for a cash payment from EarthLink to the independent director based on the increase in value of 100,000 shares of Helio Inc. common stock over the period set forth in the Stock Appreciation Right.  This Stock Appreciation Right vests over four years.

	Meeting expenses

	EarthLink reimburses directors for their expenses incurred in attending Board of Directors and Committee meetings.

	Education expenses

	EarthLink will pay up to $4,000 per year for program fees and associated travel expenses for each director to participate in one or more additional relevant director education programs.  In selecting director education programs, directors should consider general Board governance and specific Committee focus.
	Unused amounts will not carry over from year to year.Amendment & Waiver dated Sept. 27, 2006 to Amended & Restated Credit Agreement

 Exhibit 10.1 
 AMENDMENT AND WAIVER (this “Amendment”) dated as of September 27, 2006, to the Amended and Restated Credit Agreement dated as of August 4, 1999, as amended and restated as of
February 6, 2006 (as amended, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), among ON SEMICONDUCTOR CORPORATION (“Holdings”), SEMICONDUCTOR COMPONENTS
INDUSTRIES, LLC (the “Borrower”), the LENDERS party thereto, and JPMORGAN CHASE BANK, N.A., as administrative agent. 
 A.
Pursuant to the Credit Agreement, the Lenders have extended credit to the Borrower, and have agreed to extend credit to the Borrower, in each case pursuant to the terms and subject to the conditions set forth therein. 
 B. Holdings and the Borrower have requested that the Lenders agree to amend certain provisions of the Credit Agreement as set forth below.

 C. The undersigned Lenders are willing so to amend the Credit Agreement pursuant to the terms and subject to the conditions set forth
herein. 
 D. Capitalized terms used but not defined herein have the meanings assigned to them in the Credit Agreement, as amended hereby.

 Accordingly, in consideration of the mutual agreements herein contained and other good and valuable consideration, the sufficiency and
receipt of which are hereby acknowledged, and subject to the conditions set forth herein, the parties hereto hereby agree as follows: 
 SECTION 1. Amendments of Section 1.01. Section 1.01 of the Credit Agreement is hereby amended as follows: 
 (a) the definition of the term “Prepayment Event” is amended by adding, following the words “sale and leaseback transaction permitted by” appearing therein, the words “clause (a) or (b) of”.

 (b) the definition of the term “Capital Expenditures” is amended by deleting such term in its entirety and
substituting in lieu thereof the following: 
 “Capital Expenditures” means, for any period, without
duplication, (a) the additions to property, plant and equipment and other capital expenditures of the Borrower and its consolidated Subsidiaries that are (or would be) set forth in a consolidated statement of cash flows of the Borrower for such
period prepared in accordance with GAAP and (b) Capital Lease Obligations ( except for Capital Lease Obligations, if any, permitted by Section 6.06) incurred by the Borrower and its consolidated Subsidiaries during such period,
provided that the term 

 
“Capital Expenditures” (i) shall be net of landlord construction allowances, (ii) shall not include expenditures made in connection with
the repair or restoration of assets with insurance or condemnation proceeds, (iii) shall not include the purchase price of equipment to the extent consideration therefor consists of used or surplus equipment being traded in at such time or the
proceeds of a concurrent sale of such used or surplus equipment, in each case in the ordinary course of business and (iv) shall only include the portion of the expenditures of the China JV representing the Borrower’s proportionate equity
interest in the China JV. 
 SECTION 2. Amendments of Section 2.11. Paragraph (d) of Section 2.11 of the Credit
Agreement is amended by deleting such paragraph in its entirety and substituting in lieu thereof the following: 
 (d)
Following the end of each fiscal year of the Borrower, the Borrower shall prepay Term Borrowings in an aggregate amount equal to 50% of Excess Cash Flow for such fiscal year; provided that any prepayment required by this paragraph shall be
reduced, but not below zero, by the amount of any optional prepayment of the Term Borrowings pursuant to Section 2.11(a) during such fiscal year. Each prepayment pursuant to this paragraph shall be made within five Business Days after the date
on which financial statements are delivered pursuant to Section 5.01 with respect to the fiscal year for which Excess Cash Flow is being calculated (and in any event within five Business Days after the date that is 90 days after the end of
such fiscal year). Notwithstanding the foregoing, any Term Lender may elect, by notice to the Administrative Agent by telephone (confirmed by telecopy) at least one Business Day prior to the prepayment date, to decline all or any portion of any
prepayment of its Term Loans pursuant to this paragraph (d). 
 SECTION 3. Amendments of Section 6.01. Section 6.01 of the
Credit Agreement is amended by (a) deleting the word “and” appearing at the end of clause (a)(xi) thereof, (b) deleting the period at the end of clause (a)(xii) thereof and substituting in lieu thereof the following: “;
and” and (c) adding at the end of paragraph (a) thereof the following: 
 (xiii) Capital Lease Obligations of
the Borrower or any Subsidiary incurred in connection with any sale and leaseback transaction permitted by Section 6.06. 
 SECTION 4.
Amendments of Section 6.02. Section 6.02 of the Credit Agreement is amended by deleting clause (a)(vi) thereof and substituting in lieu thereof the following: 
 (vi) Liens on assets that are the subject of a capital lease of the Borrower or any Subsidiary securing Capital Lease Obligations
permitted under clause (xiii) of Section 6.01(a) in respect of such capital lease; 
  

 2 

 SECTION 5. Amendments of Section 6.04. Section 6.04 of the Credit Agreement is amended
by deleting clause (a) thereof and substituting in lieu thereof the following: 
 (a) investments by any Loan Party in
Equity Interests in any of its Subsidiaries that is not a Loan Party in an aggregate amount not to exceed $3,000,000 in any fiscal year or $10,000,000 in the aggregate; 
 SECTION 6. Amendments of Section 6.06. Section 6.06 of the Credit Agreement is amended by (a) deleting the word “and” appearing at the end of clause (a) thereof and substituting in
lieu thereof a comma and (b) adding before the period at the end thereof the following: 
 (c) any such sales and
leasebacks of equipment made in the twelve-month period commencing September 27, 2006 and ending September 26, 2007 with an aggregate fair value not to exceed $90,000,000, (d) any such sales and leasebacks of equipment
(“Replacement Equipment”) to replace damaged equipment previously sold and leased back pursuant to clause (c); provided that such Replacement Equipment shall have been purchased with insurance proceeds for such damaged
equipment and (e) any such sales and leasebacks of Replacement Equipment to replace equipment previously sold and leased back pursuant to clause (c) and subsequently moved out of the United States with an aggregate fair value not to exceed
$15,000,000 
 SECTION 7. Amendments of Section 6.08. Section 6.08 of the Credit Agreement is amended by (a) deleting
the word “and” appearing at the end of clause (b)(viii) thereof, (b) deleting the period at the end of clause (b)(ix) thereof and substituting in lieu thereof the following: “; and” and (c) adding at the end of
paragraph (b) thereof the following: 
 (x) payments of up to $100,000 in respect of the purchase, redemption or
retirement of any Permitted Convertible Debt. 
 SECTION 8. Amendments of Section 6.14. Section 6.14 of the Credit Agreement
is amended by deleting the amount “$40,000,000” set forth in clause (d) thereof and substituting in lieu thereof the amount “$50,000,000”. 
 SECTION 9. Amendments of Schedule 6.02. Schedule 6.02 of the Credit Agreement is amended by deleting such Schedule in its entirety and substituting in lieu thereof Schedule 6.02 attached as Exhibit A hereto.

 SECTION 10. Representations and Warranties. Each of Holdings and the Borrower represents and warrants to the Administrative Agent
and to each of the Lenders that: 
 (a) This Amendment has been duly authorized, executed and delivered by each of Holdings
and the Borrower and constitutes a legal, valid and binding obligation of Holdings and the Borrower, enforceable in accordance with its terms, 

  

 3 

 
subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general
principles of equity, regardless of whether considered in a proceeding in equity or at law. 
 (b) After giving effect to this
Amendment, each of the representations and warranties of Holdings and the Borrower set forth in the Loan Documents is true and correct on and as of the date hereof, except to the extent such representations and warranties expressly relate to an
earlier date, in which case such representations and warranties are true and correct as of such earlier date. 
 (c)
Immediately after giving effect to this Amendment, no Default shall have occurred and be continuing. 
 SECTION 11. Conditions to
Effectiveness. This Amendment shall become effective on the date that the following conditions shall have occurred (which date shall not be later than September 27, 2006): (a) the Administrative Agent shall have received
counterparts of this Amendment that, when taken together, bear the signatures of Holdings, the Borrower and the Required Lenders, and (b) all fees and other amounts due and payable in connection with this Amendment or the Credit Agreement,
including the fee described in Section 12 and, to the extent invoiced in writing to the Borrower at least two Business Days prior to such date, reimbursement or payment of all reasonable, documented, out-of-pocket expenses (including fees,
charges and disbursements of counsel or other advisors) required to be paid or reimbursed by any Loan Party, shall have been paid or reimbursed, as applicable. 
 SECTION 12. Amendment Fee. In consideration of the agreements of the Lenders contained in this Amendment, the Borrower agrees to pay to the Administrative Agent, for the account of each Lender that delivers an
executed counterpart of this Amendment at or prior to 5:00 p.m., New York time, on September 27, 2006, an amendment fee in an amount equal to 0.05% of the sum of such Lender’s Revolving Commitment and outstanding Term Loans;
provided that such fee shall not be payable unless and until all conditions to the effectiveness of this Amendment as provided in Section 11 (other than payment of such amendment fee) shall have been satisfied. 
 SECTION 13. Waiver of Notice. The Administrative Agent and the undersigned Lenders hereby waive the notice requirements of Section 2.11(e)
and (f) of the Credit Agreement in respect of any voluntary prepayments of the Term Loans made by the Borrower prior to September 30, 2006. 
 SECTION 14. Credit Agreement. Except as specifically amended hereby, the Credit Agreement shall continue in full force and effect in accordance with the provisions thereof as in existence on the date hereof.
After the date hereof, any reference to the Credit Agreement shall mean the Credit Agreement as amended or modified hereby. This Amendment shall be a Loan Document for all purposes. 
  

 4 

 SECTION 15. Applicable Law; Waiver of Jury Trial. (A) THIS AMENDMENT SHALL BE GOVERNED BY,
AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 
 (B) EACH PARTY HERETO HEREBY AGREES AS SET FORTH IN SECTION
9.10 OF THE CREDIT AGREEMENT AS IF SUCH SECTION WERE SET FORTH IN FULL HEREIN. 
 SECTION 16. Counterparts. This Amendment may be
executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one agreement. Delivery of an executed signature page to this Amendment by facsimile or other electronic
transmission shall be effective as delivery of a manually signed counterpart of this Amendment. 
 SECTION 17. Expenses. The Borrower
agrees to reimburse the Administrative Agent for its reasonable, documented, out-of-pocket expenses in connection with this Amendment, including the reasonable fees, charges and disbursements of Cravath, Swaine & Moore LLP, counsel for the
Administrative Agent. 
 SECTION 18. Headings. The Section headings used herein are for convenience of reference only, are not part of
this Amendment and are not to affect the construction of, or to be taken into consideration in interpreting, this Amendment. 
  

 5 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective
authorized officers as of the day and year first written above. 
  

					
	 ON SEMICONDUCTOR CORPORATION,

		
	By	 	 /s/ DONALD A. COLVIN

		 	 Name:
	 	 Donald A. Colvin

		 	 Title:
	 	 Executive Vice President and

		 		 	 Chief Financial Officer

	
	SEMICONDUCTOR COMPONENTS INDUSTRIES, LLC,
		
	By	 	 /s/ DONALD A. COLVIN

		 	 Name:
	 	 Donald A. Colvin

		 	 Title:
	 	 Executive Vice President and

		 		 	 Chief Financial Officer

	
	 JPMORGAN CHASE BANK, N.A.,
 individually and
as administrative agent,

		
	By	 	 /s/ PETER M. LING

		 	 Name:
	 	 Peter M. Ling

		 	 Title:
	 	 Managing Director

  

 6 

			
	SIGNATURE PAGE TO AMENDMENT AND WAIVER DATED AS OF SEPTEMBER 27, 2006, TO THE CREDIT AGREEMENT DATED AS OF AUGUST 4, 1999, AS AMENDED AND RESTATED AS OF FEBRUARY 6, 2006, AMONG
ON SEMICONDUCTOR CORPORATION, SEMICONDUCTOR COMPONENTS INDUSTRIES, LLC, THE LENDERS PARTY THERETO, AND JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
		
	Name of Institution:	 	  

			
		
	By	 	  
		 	 Name:

		 	 Title:

 [Multiple signature pages of the various lending institutions make 
 up the remainder of the amendment and are not reproduced here.] 
  

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]